ATE271393T1 - Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern - Google Patents

Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern

Info

Publication number
ATE271393T1
ATE271393T1 AT97120135T AT97120135T ATE271393T1 AT E271393 T1 ATE271393 T1 AT E271393T1 AT 97120135 T AT97120135 T AT 97120135T AT 97120135 T AT97120135 T AT 97120135T AT E271393 T1 ATE271393 T1 AT E271393T1
Authority
AT
Austria
Prior art keywords
drugs
compositions
increasing
skin penetration
permeation accelerators
Prior art date
Application number
AT97120135T
Other languages
English (en)
Inventor
Prakash Parab
Cheng Der Tony Yu
Bhiku Patei
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE271393T1 publication Critical patent/ATE271393T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT97120135T 1996-11-18 1997-11-17 Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern ATE271393T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/751,293 US6019988A (en) 1996-11-18 1996-11-18 Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage

Publications (1)

Publication Number Publication Date
ATE271393T1 true ATE271393T1 (de) 2004-08-15

Family

ID=25021358

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97120135T ATE271393T1 (de) 1996-11-18 1997-11-17 Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern

Country Status (14)

Country Link
US (1) US6019988A (de)
EP (1) EP0857488B1 (de)
KR (1) KR19980042501A (de)
CN (1) CN1152672C (de)
AR (1) AR009428A1 (de)
AT (1) ATE271393T1 (de)
AU (1) AU742996B2 (de)
BR (1) BR9705487A (de)
CA (1) CA2220377A1 (de)
DE (1) DE69729932T2 (de)
ES (1) ES2225926T3 (de)
MX (1) MX9708722A (de)
NZ (1) NZ329184A (de)
ZA (1) ZA9710267B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
US6306383B1 (en) * 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
WO2001032115A1 (en) * 1999-11-04 2001-05-10 Xel Herbaceuticals Transdermal administration of huperzine
US6645520B2 (en) 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
US6719997B2 (en) 2000-06-30 2004-04-13 Dermatrends, Inc. Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers
US6562370B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6562369B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6673363B2 (en) * 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6565879B1 (en) * 1999-12-16 2003-05-20 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
US6602912B2 (en) 2000-06-30 2003-08-05 Dermatrends, Inc. Transdermal administration of phenylpropanolamine
US6586000B2 (en) * 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
WO2002011784A2 (en) * 2000-08-07 2002-02-14 Transdermics Ltd. Pharmaceutical carriers and compositions for transdermal drug delivery
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US20020198215A1 (en) * 2000-10-23 2002-12-26 Lino Tavares Terazosin transdermal device and methods
US6635274B1 (en) * 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
WO2002074310A2 (en) * 2001-01-19 2002-09-26 Johnson & Johnson Consumer Companies, Inc. Stabilized formulation of selective ligands of retinoic acid gamma-receptors
WO2003009805A2 (en) * 2001-07-23 2003-02-06 Brigham And Women's Hospital, Inc. Analgesic methods using endothelin receptor ligands
US20030021835A1 (en) * 2001-07-24 2003-01-30 Ancel Surgical R&D, Inc. Medical patch with burstable partition
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
MXPA04011584A (es) * 2002-05-23 2005-03-31 Umd Inc Composiciones y metodo para la administracion y crioproteccion de drogas transmucosales.
CN1207005C (zh) * 2002-10-31 2005-06-22 威世药业（如皋）有限公司 含生物活性物质的兔皮和其用途
EP1635770B1 (de) * 2003-03-21 2009-05-27 Nexmed Holdings, Inc. Antimykotischer nagellack und anwendungsverfahren
US20050042182A1 (en) * 2003-08-13 2005-02-24 Moshe Arkin Topical compositions of urea
US20050036953A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of ammonium lactate
US20050037040A1 (en) * 2003-08-13 2005-02-17 Moshe Arkin Topical compositions of urea and ammonium lactate
US20050025833A1 (en) * 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) * 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050014823A1 (en) * 2003-07-17 2005-01-20 Soderlund Patrick L. Topical anesthetic composition and method of administration
MXPA06004827A (es) * 2003-10-31 2006-07-03 Procter & Gamble Metodo para proveer una composicion combinada.
DE602005025755D1 (de) 2004-06-04 2011-02-17 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
DE102004062614B4 (de) * 2004-12-24 2011-12-29 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit aktivierbarer Übersättigung und kontrollierter Permeationförderung sowie Verfahren zu dessen Herstellung
WO2006109194A2 (en) * 2005-01-27 2006-10-19 Ocean Nutrition Canada Ltd. Chromium-fatty acid compounds and methods of making and using thereof
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
WO2007005469A2 (en) * 2005-06-29 2007-01-11 Jr Chem, Llc Method of enhanced benzoyl peroxide application
US9968120B2 (en) * 2006-05-17 2018-05-15 Dsm Nutritional Products Ag Homogenized formulations containing microcapsules and methods of making and using thereof
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
GEP20125432B (en) 2005-10-12 2012-03-26 Unimed Pharmaceuticals Llc Improved testosterone gel and use thereof
DE102005050431A1 (de) * 2005-10-21 2007-04-26 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreicherung lipophiler und/oder wenig hautpermeabler Wirkstoffe
GB0524121D0 (en) * 2005-11-26 2006-01-04 Namibia Medical Invest Pty Ltd Patch
EP1998742A2 (de) * 2006-03-08 2008-12-10 Nuviance, INC. Zusammensetzungen für transdermale wirkstofffreisetzung und topische zusammensetzungen zum auftragen auf die haut
WO2007120500A2 (en) * 2006-04-07 2007-10-25 Ocean Nutrition Canada Ltd. Emulsions and microcapsules with substances having low interfacial tension, methods of making and using thereof
MX306461B (es) * 2006-06-05 2013-01-07 Ocean Nutrition Canada Ltd Microcapsulas con cubiertas mejoradas
US20090304776A1 (en) * 2008-06-06 2009-12-10 Totada Shantha Transmucosal delivery of therapeutic agents and methods of use thereof
EP2654638A4 (de) * 2010-12-20 2014-07-02 Polytherapeutics Inc Zusammensetzung zur transdermalen verabreichung eines nichtsteroiden entzündungshemmenden wirkstoffs
HK1219533A1 (zh) 2013-03-15 2017-04-07 Intermune, Inc. 蛋白质组学ipf标志物
TWI593411B (zh) 2013-04-30 2017-08-01 徐懷山 組合物於製備抑制雄性素受體有關之功能及治療雄性素 受體相關之疾病的藥物之用途
WO2016105499A1 (en) 2014-12-23 2016-06-30 Intellectual Property Associates, Llc Methods and formulations for transdermal administration
US11337745B2 (en) 2018-05-29 2022-05-24 Ilooda Co., Ltd. Device for treatment of acne and control method of the same
CN113164321A (zh) * 2018-10-04 2021-07-23 米拉基创新智库有限责任公司 治疗皮下脂肪层的方法
KR102256054B1 (ko) 2019-03-21 2021-05-25 (주)심플스틱 골드입자를 이용한 여드름 개선방법
CN115515559B (zh) * 2019-12-20 2026-03-24 翻译生物公司 信使rna的直肠递送
KR20230106667A (ko) * 2020-11-18 2023-07-13 마이크로캡스 아게 봉입 오일 코어 마이크로캡슐

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497794A (en) * 1980-12-08 1985-02-05 Dermik Laboratories, Inc. Erythromycin/benzoyl peroxide composition for the treatment of acne
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4931283A (en) * 1983-12-22 1990-06-05 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4592487A (en) * 1985-07-03 1986-06-03 Simon Gilbert I Dentifrices
FR2586913B1 (fr) * 1985-09-10 1990-08-03 Oreal Procede pour former in situ une composition constituee de deux parties conditionnees separement et ensemble distributeur pour la mise en oeuvre de ce procede
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
EP0252459A1 (de) * 1986-07-07 1988-01-13 Schering Corporation Kompartimentiertes transdermales Abgabesystem
US4911707A (en) * 1987-02-13 1990-03-27 Ciba-Geigy Corporation Monolithic user-activated transdermal therapeutic system
US5422119A (en) * 1987-09-24 1995-06-06 Jencap Research Ltd. Transdermal hormone replacement therapy
US5028431A (en) * 1987-10-29 1991-07-02 Hercon Laboratories Corporation Article for the delivery to animal tissue of a pharmacologically active agent
US5223262A (en) * 1989-02-23 1993-06-29 University Of Utah Transdermal delivery system utilizing one way membranes
WO1990009809A1 (en) * 1989-02-23 1990-09-07 University Of Utah Percutaneous drug delivery system
US5156846A (en) * 1989-02-23 1992-10-20 University Of Utah Percutaneous drug delivery system
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
GB9025711D0 (en) * 1990-11-27 1991-01-09 Beecham Group Plc Topical composition
US5174475A (en) * 1991-03-26 1992-12-29 Glaxo Inc. Sequential dosing of antifungal and antiinflammatory compositions
US5326566A (en) * 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
US5436369A (en) * 1993-06-16 1995-07-25 Bristol-Myers Squibb Company Alicyclic phospholipase A2 inhibitors
ES2074030B1 (es) * 1994-01-31 1996-02-01 S A L V A T Lab Sa Composiciones portadoras, autocalentadoras y aplicables en terapeutica por via topica.
US5538732A (en) * 1994-04-12 1996-07-23 Creative Products Resource, Inc. Medicated applicator sheet for topical drug delivery
DE4435805A1 (de) * 1994-10-06 1996-04-11 Knoll Ag Zweikomponenten-Creme

Also Published As

Publication number Publication date
AR009428A1 (es) 2000-04-12
EP0857488A3 (de) 1999-08-25
US6019988A (en) 2000-02-01
AU742996B2 (en) 2002-01-17
EP0857488A2 (de) 1998-08-12
ZA9710267B (en) 1999-05-13
AU4520097A (en) 1998-05-21
BR9705487A (pt) 1999-04-06
DE69729932T2 (de) 2005-08-25
MX9708722A (es) 1998-07-31
ES2225926T3 (es) 2005-03-16
NZ329184A (en) 1999-03-29
CA2220377A1 (en) 1998-05-18
CN1152672C (zh) 2004-06-09
DE69729932D1 (de) 2004-08-26
EP0857488B1 (de) 2004-07-21
KR19980042501A (ko) 1998-08-17
CN1190001A (zh) 1998-08-12

Similar Documents

Publication Publication Date Title
ATE271393T1 (de) Zusammensetzungen zur erhöhung des hautdurchtritts von arzneistoffen unter verwendung von permeationsbeschleunigern
ATE297754T1 (de) Heilung von bruchverletzungen unter verwendung von pthrp analogen
DE69926686D1 (de) Vorrichtung zur Verabreichung von hochkonzentrierten NO Pulsen
DE69634519D1 (de) Katheter zur ablation von atrio-ventikulären gewebe
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE69629948D1 (de) Vorrichtung zur ablation von gewebemassen
DE69826705D1 (de) Verfahren zur dermalen verabreichung von polypeptiden
ATE253361T1 (de) Mittel zur gesteuerten freisetzung von paroxetin
DE69725169D1 (de) Zusammensetzungen und verfahren zur anregung des wachstums von neuriten
DE69713295D1 (de) Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
DE69739418D1 (de) System zur Herstimulussteuerung
DE60015734D1 (de) Verwendung von dinukleotidtriphosphaten, cytidindiphosphaten und adenindiphosphaten zur herstellung einer pharmazeutischen zubereitung zur förderung der schleimauthydratation
DE69739258D1 (de) Verfahren zur Herstellung von Polyelektrolyten
DE59708165D1 (de) Verfahren zur Herstellung von Diarylcarbonaten
DE69940256D1 (de) Zusammensetzung zur hautbleichung
DE69720379D1 (de) Verfahren zur Herstellung von Erythritol
DE69812784D1 (de) Zusammensetzung zur Vorbeugung und Beseitigung von Pflanzenkrankheiten
DE69707607D1 (de) Enzymbehandeltes Hesperidin, Verfahren zur Herstellung und Verfahren zur Verwendung von enzymbehandeltem Hesperidin
DE69522349D1 (de) Von der Haut leicht abnehmbares Pflaster zur transdermalen Anwendung
DE69434777D1 (de) Verwendung von Relaxin zur Herstellung von therapeutischen Mitteln
DE69737067D1 (de) Vakzine zur behandlung von mycosen
DE69716223D1 (de) Vorrichtung zur Herstellung von medizinischen Pflastern zur perkutanen Verabreichung
DE69813612D1 (de) Automatisches system zur erstellung und verwaltung von strafzetteln
DE19881185D2 (de) Vorrichtung zur Zerstörung bzw. Zertrümmerung von Konkrementen
DE69804572D1 (de) Verfahren zur Herstellung von Bisphenol-A

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0857488

Country of ref document: EP

REN Ceased due to non-payment of the annual fee